Need professional-grade analysis? Visit stockanalysis.com
$2.78B
N/A
N/A
N/A
Tango Therapeutics Inc (TNGX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $23.48, up 2.00% from the previous close.
Over the past year, TNGX has traded between a low of $1.28 and a high of $27.77. The stock has gained 1577.1% over this period. It is currently 15.4% below its 52-week high.
Tango Therapeutics Inc has a market capitalization of $2.78B.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Side-by-side comparison against top Healthcare peers.